Table 1 Characteristics of the patients
From: MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
| Â | Training set | Test set | ||
|---|---|---|---|---|
| Â | Not Responder group | Complete Responder group | Not Responder group | Complete Responder group |
| Â | n = 8 | n = 9 | n = 5 | n = 7 |
Male, n(%) | 7 (87.5%) | 6 (66.6%) | 4 (80%) | 2 (28.6%) |
Female, n(%) | 1 (12.5%) | 3 (33.3%) | 1 (20%) | 5 (71.4%) |
Median age at diagnosis, years(range) | 67,5 (35-80) | 66 (40-85) | 68 (61-76) | 60 (37-78) |
11qdel, n(%) | 0 (0%) | 2 (22.2%) | 0 (0%) | 0 (0%) |
17pdel, n(%) | 2 (25%) | 1 (11.1%) | 3 (60%) | 0 (0%) |
Previous lines of therapy, n (%) (clorambucil) | 8 (100%) | 5 (55.5%) | 4 (80%) | 3 (42.9%) |
Rai Stage, n (%) | Â | Â | Â | Â |
0-I | 7 (87.5%) | 9 (100%) | 2 (40%) | 4 (57.1%) |
II-IV | 1 (12.5%) | 0 (0%) | 3 (60%) | 3 (42.9%) |
Time to Treatment (months) | 35.6 (0-75) | 17.0 (0-56) | 7.7 (0-20) | 32.2 (10-75) |